Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02
- Author(s)
- Hurvitz, SA; Loi, S; O'Shaughnessy, J; Okines, AFC; Tolaney, SM; Sohn, J; Saura, C; Zhu, X; Cameron, D; Bachelot, T; Hamilton, E; Curigliano, G; Wolff, AC; Harbeck, N; Masuda, N; Vahdat, L; Zaman, K; Valdes-Albini, F; Block, M; Pluard, T; Tan, TJ; Gawryletz, C; Chan, A; Bedard, PL; Yerushalmi, R; Xu, B; Schmitt, M; Xie, D; Borges, VF; HER2CLIMB-02 study investigators;
- Journal Title
- Annals of Oncology
- Publication Type
- Online publication before print
- Abstract
- BACKGROUND: Trastuzumab emtansine (T-DM1) is a standard treatment option in patients with previously treated human epidermal growth factor receptor 2-positive (HER2+) locally advanced or metastatic breast cancer (LA/MBC). Here, we report the efficacy and safety of tucatinib in combination with T-DM1 compared with T-DM1 alone from the phase III HER2CLIMB-02 study (NCT03975647). PATIENTS AND METHODS: Eligible patients had HER2+ LA/MBC that had been previously treated with trastuzumab and a taxane in any setting; these included patients with brain metastases (BMs). Patients were randomly assigned 1:1 to receive T-DM1 (3.6 mg/kg intravenously every 21 days) combined with either tucatinib (300 mg orally twice daily) in the tucatinib arm or placebo (orally twice daily) in the control arm. RESULTS: In total, 463 patients were randomly assigned. After a median follow-up duration of 24.4 months, the median progression-free survival (PFS) was 9.5 months in the tucatinib arm and 7.4 months in the control arm (hazard ratio [HR]=0.76; 95% CI, 0.61-0.95; P=0.0163). A PFS benefit was observed across all prespecified subgroups, including in patients with BMs. Interim overall survival analysis results were immature. The median OS was not reached in the tucatinib arm and was 38.0 months in the control arm (HR=1.23; 95% CI, 0.87-1.74). The incidences of treatment-emergent adverse events (TEAEs) associated with any treatment discontinuation and of grade ≥3 TEAEs were higher in the tucatinib arm than in the control arm (22.1% versus 11.6% and 68.8% versus 41.2%, respectively). The most common grade ≥3 TEAEs in the tucatinib arm were elevated alanine aminotransferase (16.5%) and aspartate aminotransferase levels (16.5%) (versus 2.6% for both in the control arm). CONCLUSION: The addition of tucatinib to T-DM1 improved PFS in patients with previously treated HER2+ LA/MBC, including patients with BMs, and exhibited a manageable safety profile.
- Keywords
- T-dm1; advanced/metastatic breast cancer; brain metastases; human epidermal growth factor receptor 2–positive; trastuzumab emtansine; tucatinib
- Department(s)
- Medical Oncology; Laboratory Research
- Publisher's Version
- https://doi.org/10.1016/j.annonc.2025.11.005
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-12-05 02:49:44
Last Modified: 2025-12-05 02:55:47